Lupin surges after new drug launch in the US

Lupin announced that its US subsidiary Lupin Pharmaceutical Inc. has launched its Tri-Lo-Marzia Tablets (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg) having received approval from the United States Food and Drug Administration.

Shares of Lupin are currently trading 0.21% higher at Rs. 1,757.75 on BSE after the company launched oral contraceptive in the US. Heavy sell-off in Asian markets across all sectors due to Chinese stock markets suspending trading could not affect the company’s stocks.  

The scrip opened higher at Rs. 1,755.05 as against its previous close of Rs. 1,754.15. It hit a high and a low of Rs. 1,769.35 and Rs. 1,742.60 respectively. Total 24,000 shares changed hands on BSE.

Lupin announced that its US subsidiary Lupin Pharmaceutical Inc. has launched its Tri-Lo-Marzia Tablets (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg) having received approval from the United States Food and Drug Administration (FDA) to market a generic equivalent of Janssen Pharmaceuticals Inc. (Janssen) Ortho Tri-Cyclen Lo Tablets, (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg). 

Lupin's Tri-Lo-Marzia Tablets (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg) are the AB rated generic equivalent of Janssen Ortho Tri-Cyclen Lo Tablets, (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg). It is indicated for use by women to prevent pregnancy. 

According to IMS MAT September 2015, Ortho Tri-Cyclen Lo Tablets had US sales of US$ 488.4 million. The product represents Lupin’s 16th oral contraceptive launch in the US. The company has filed 37 oral contraceptive products with the FDA till date.